Our sister publication, Patient Care, analyzed a recent study on the connection between cannabis use and asthma in adolescents and adults in the US.
A recent cross-sectional survey conducted by researchers from three different institutions aimed to gauge how common asthma is in adolescents and adults who had used cannabis within the past 30 days (1). Noting that there is a rise in cannabis use in this population but an absence of data on the prevalence of asthma with cannabis use, the researchers reviewed data from over 30,000 individuals ages 12 and older to provide more research in this area (1). The study, titled “Cannabis use and the prevalence of current asthma among adolescents and adults in the United States,” was published in the journal Preventative Medicine in December 2023 (1).
The researchers analyzed data from the National Survey on Drug Use and Health from 2020, adjusting for demographics and cigarette smoking (1). They also examined the effect of frequency of use and of blunt use (1).
Analysis from our sister publication Patient Care states (2):
Read the original article from Patient Care for more analysis and results: https://www.patientcareonline.com/view/use-of-cannabis-linked-to-high-risk-of-prevalent-asthma-new-findings
References
Ep 25: Cannabis Quality Differentiation Beyond Cannabinoid Content
February 28th 2025In this latest installment of Noid Knowledge we are joined by Julie Kowalski, a leading mind in analytical chemistry and cannabis testing. Julie has arranged a very compelling symposium for Pittcon entitled Cannabis Aroma: Advances and Challenges in Determining and Commercializing Cannabis Product Quality Attributes. It is taking place on Wednesday, March 5, 2025, starting at 9:30 AM in room 209. The session features top notch speakers, including several previous guests of this show, and yours truly, discussing the next generation of quality assessment in cannabis.
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.